Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant
Olivier Demaria, Laurent Gauthier, Marie Vétizou, Audrey Blanchard Alvarez, Constance Vagne, Guillaume Habif, Luciana Batista, William Baron, Nourhène Belaïd, Mathilde Girard-Madoux, Cédric Cesari, Mélody Caratini, Frédéric Bosco, Olivier Bénac, Julie Lopez, Aurore Fenis, Justine Galluso, Sylvia Trichard, Barbara Carrette, Florent Carrette, Aurélie Maguer, Solène Jaubert, Audrey Sansaloni, Robin Letay-Drouet, Camille Kosthowa, Naouel Lovera, Arnaud Dujardin, Fabien Chanuc, Mélanie Le Van, Sivan Bokobza, Nicolas Jarmuzynski, Camille Fos, Nicolas Gourdin, Romain Remark, É. Lechevallier, Nicolas Fakhry, Sébastien Salas, Jean‐Laurent Deville, Roger Le Grand, Cécile Bonnafous, Lukas Vollmy, Agnès Représa, Sabrina Carpentier, Benjamín Rossi, Ariane Morel, Stéphanie Cornen, Ivan Perrot, Yannis Morel, Éric Vivier
Abstract
circulating B cell depletion, with minimal systemic cytokine release and no sign of toxicity. Tetraspecific ANKETs, thus, constitute a technological platform for harnessing NK cells as next-generation cancer immunotherapies.